This Article Full Text Full Text (PDF) Purchase Article View Shopping Cart Alert me when this article is cited Alert me if a correction is posted Services Email this article to a colleague Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Save to my personal folders Download to citation manager Rights & Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Hecht, J. L. Articles by Mutter, G. L. Search for Related Content PubMed PubMed Citation Articles by Hecht, J. L. Articles by Mutter, G. L. Social Bookmarking                            What's this?

Molecular and Pathologic Aspects of Endometrial Carcinogenesis

Jonathan L. Hecht, George L. Mutter

From the Department of Pathology, Beth Israel Hospital; Department of Pathology, Brigham and Women's Hospital, Boston, MA

Address reprint requests to Department of Pathology, Beth-Israel Deaconess Medical Center, 330 Brookline Ave, Boston, MA 02215; e-mail: jlhecht{at}BIDMC.harvard.edu

Endometrial cancer is the most common gynecological malignancy, with 41,000 new cases projected in the United States for 2006. Two different clinicopathologic subtypes are recognized: the estrogen-related (type I, endometrioid) and the non–estrogen-related types (type II, nonendometrioid such as papillary serous and clear cell). The morphologic differences in these cancers are mirrored in their molecular genetic profile with type I showing defects in DNA-mismatch repair and mutations in PTEN, K-ras, and beta-catenin, and type II showing aneuploidy and p53 mutations. This article reviews the genetic aspects of endometrial carcinogenesis and progression. We will define the precursor lesion of type I endometrioid cancer and the role of genetics and estrogen in its progression.

Terms in blue are defined in the glossary, found at the end of this article and online at www.jco.org.

Authors' disclosures of potential conflicts of interest and author contributions are found at the end of this article.

CiteULike    Complore    Connotea    Del.icio.us    Digg    Facebook    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				P. Chaudhry and E. Asselin Resistance to chemotherapy and hormone therapy in endometrial cancer Endocr. Relat. Cancer, June 1, 2009; 16(2): 363 - 380. [Abstract] [Full Text] [PDF]

				E. Samuelson, C. Hedberg, S. Nilsson, and A. Behboudi Molecular classification of spontaneous endometrial adenocarcinomas in BDII rats Endocr. Relat. Cancer, March 1, 2009; 16(1): 99 - 111. [Abstract] [Full Text] [PDF]

				M. Mancuso, D. Gallo, S. Leonardi, M. Pierdomenico, E. Pasquali, I. De Stefano, S. Rebessi, M. Tanori, G. Scambia, V. Di Majo, et al. Modulation of basal and squamous cell carcinoma by endogenous estrogen in mouse models of skin cancer Carcinogenesis, February 1, 2009; 30(2): 340 - 347. [Abstract] [Full Text] [PDF]

				V. L. Bae-Jump, Chunxiao Zhou, J. F. Boggess, and P. A. Gehrig Arsenic Trioxide (As2O3) Inhibits Expression of Estrogen Receptor--alpha Through Regulation of the Mitogen-activated Protein Kinase (MAPK) Pathway in Endometrial Cancer Cells Reproductive Sciences, December 1, 2008; 15(10): 1011 - 1017. [Abstract] [PDF]

				K. Shimazaki, E. J. Lepin, B. Wei, A. K. Nagy, C. P. Coulam, S. Mareninov, M. Fu, A. M. Wu, J. D. Marks, J. Braun, et al. Diabodies Targeting Epithelial Membrane Protein 2 Reduce Tumorigenicity of Human Endometrial Cancer Cell Lines Clin. Cancer Res., November 15, 2008; 14(22): 7367 - 7377. [Abstract] [Full Text] [PDF]

				S. A. Byron, M. G. Gartside, C. L. Wellens, M. A. Mallon, J. B. Keenan, M. A. Powell, P. J. Goodfellow, and P. M. Pollock Inhibition of Activated Fibroblast Growth Factor Receptor 2 in Endometrial Cancer Cells Induces Cell Death Despite PTEN Abrogation Cancer Res., September 1, 2008; 68(17): 6902 - 6907. [Abstract] [Full Text] [PDF]

				E. A. Akbay, C. M. Contreras, S. A. Perera, J. P. Sullivan, R. R. Broaddus, J. O. Schorge, R. Ashfaq, H. Saboorian, K.-K. Wong, and D. H. Castrillon Differential Roles of Telomere Attrition in Type I and II Endometrial Carcinogenesis Am. J. Pathol., August 1, 2008; 173(2): 536 - 544. [Abstract] [Full Text] [PDF]

				M. Matsumoto, Y. Yamaguchi, Y. Seino, A. Hatakeyama, H. Takei, H. Niikura, K. Ito, T. Suzuki, H. Sasano, N. Yaegashi, et al. Estrogen signaling ability in human endometrial cancer through the cancer-stromal interaction Endocr. Relat. Cancer, June 1, 2008; 15(2): 451 - 463. [Abstract] [Full Text] [PDF]

				T. K. Nayak, H. J. Hathaway, C. Ramesh, J. B. Arterburn, D. Dai, L. A. Sklar, J. P. Norenberg, and E. R. Prossnitz Preclinical Development of a Neutral, Estrogen Receptor-Targeted, Tridentate 99mTc(I)-Estradiol-Pyridin-2-yl Hydrazine Derivative for Imaging of Breast and Endometrial Cancers J. Nucl. Med., June 1, 2008; 49(6): 978 - 986. [Abstract] [Full Text] [PDF]

				E. C. Ward, A. V. Hoekstra, L. J. Blok, P. Hanifi-Moghaddam, J. R. Lurain, D. K. Singh, B. M. Buttin, J. C. Schink, and J. J. Kim The Regulation and Function of the Forkhead Transcription Factor, Forkhead Box O1, Is Dependent on the Progesterone Receptor in Endometrial Carcinoma Endocrinology, April 1, 2008; 149(4): 1942 - 1950. [Abstract] [Full Text] [PDF]

				N Horree, P J van Diest, P van der Groep, D M D S Sie-Go, and A P M Heintz Progressive derailment of cell cycle regulators in endometrial carcinogenesis J. Clin. Pathol., January 1, 2008; 61(1): 36 - 42. [Abstract] [Full Text] [PDF]